Earnings Preview: Medco Health Solutions
NEW YORK — Medco Health Solutions Inc., the largest U.S. pharmacy benefits manager, is scheduled to report its third-quarter results Tuesday morning. The following is a summary of key developments and analyst commentary for the period.
OVERVIEW: Medco, of Franklin Lakes, N.J., makes money by designing benefits packages for plan sponsors and members. Profits have improved despite the recession because companies are looking for ways to cut their health care costs. Demand for low-cost generic drugs and mail order prescriptions, which are strongly profitable for Medco, has increased.
Strong sales of pricey specialty drugs has also helped Medco in recent quarters. The recession has affected demand for brand-name drugs, but pharmaceutical companies have gotten more aggressive in raising their prices of late, because many top-selling drugs will lose patent protection starting in 2011.
A year ago, the company earned 58 cents per share on revenue of $12.56 billion.
BY THE NUMBERS: Analysts polled by Thomson Reuters expect a profit of 72 cents per share and $14.68 billion in revenue.
ANALYST TAKE: Deutsche Bank analyst Ross Muken said he expects continued growth in generic sales, mail order prescription filling and specialty drug revenue.
“Medco remains the best organic growth story in the space,” he wrote in a note to clients.
WHAT’S AHEAD: Three months ago, Medco raised its profit forecast to a range of $2.76 to $2.81 per share. Analysts currently expect $2.80 per share, on average.
The company said it will provide guidance for 2010, and analysts will be evaluating Medco’s success at winning over new clients.
“The PBMs had a spectacular fiscal 2009 selling season, particularly for Medco, which had its best year for new business wins,” Muken wrote. “This trend has continued into 2010, as more clients become convinced about the PBM value proposition.” The analyst added that he does not think Medco or rival Express Scripts are facing too much pressure to cut prices.
STOCK PERFORMANCE: Medco shares jumped 21 percent during the third quarter, closing at $55.31. The stock set an annual high of $58.16 on Oct. 23 and closed at $56.12 Friday.
Related News
AstraZeneca posts 22 percent rise in third quarter profits amid demand for swine flu vaccineOctober 29th, 2009 more images
more images
AstraZeneca 3Q earns up 22 percent
LONDON — Pharmaceutical company AstraZeneca PLC posted a 22 percent rise in third quarter net profit on Thursday, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States. The expectation of further profits expected from its Novel Influenza A vaccine for the H1N1 led AstraZeneca to lift its full-year earnings forecast.
Hospira profit climbs on sales of generic chemotherapy treatment and other specialty drugsOctober 27th, 2009 more images
more imagesChemotherapy drug sales boost Hospira 3Q profitLAKE FOREST, Ill. — Hospira Inc.
Bharat Biotech's rabies vaccine to touch 20 million dosesOctober 27th, 2009 HYDERABAD - City-based vaccines and biotherapeutics manufacturer Bharat Biotech expects to more than double sales of its anti-rabies vaccine, INDIRAB(r),in two years to touch 20 million doses. INDIRAB sales crossed the 10-million-dose mark in a period of three years.
Shire says FDA reaffirms 5-year market exclusivity period for ADHD drug VyvanseOctober 26th, 2009 Shire says FDA reaffirms Vyvanse exclusivityNEW YORK — Shire PLC said the U.S. Food and Drug Administration reaffirmed a prior decision to give the attention-deficit-hyperactivity disorder drug Vyvanse five-years of market exclusivity.
Amgen shares fall as company discloses additional FDA Prolia request, Arenesp dataOctober 22nd, 2009 Amgen shares fall after new Prolia requestNEW YORK — Amgen Inc. shares fell Thursday over the likelihood that the biotechnology company's next potential blockbuster will take longer than expected to reach its full sales potential in the market.
3M posts weaker 3Q profit because of frugal US, European consumers but Asia offers a boostOctober 22nd, 2009 3M's 3Q weaker but Asia provides surprising boostNEW YORK — 3M Co., which makes everything from Post-It Notes to insect repellent, said Thursday strong sales of health care products in flu-wary Asia helped lift earnings beyond analyst expectations in the third quarter. As a result, the St.
Amgen's 3rd-quarter profit rises 24 percent on lower costs as anemia drug sales continue dropOctober 21st, 2009 Amgen 3Q profit jumps 24 percent on lower costsNEW YORK — Biotechnology company Amgen Inc. said Wednesday lower costs in its research and sales units boosted third-quarter profit by 24 percent, despite a continued downturn in anemia drug sales.
Eli Lilly 3rd-quarter profit and revenue surpass estimates, drugmaker raises 2009 guidanceOctober 21st, 2009 Eli Lilly posts 3Q profit ahead of forecastsINDIANAPOLIS — Eli Lilly & Co. said Wednesday it turned a profit in the third quarter as sales volume on several drugs climbed, but its newest drug and key source of future revenue started slowly.
Biogen Idec says Tysabri sales grew 21 pct, lower amortization expenses aided 3rd-qtr profitOctober 20th, 2009 Biogen 3Q profit beats views on smaller chargesCAMBRIDGE, Mass. — Biogen Idec says its profit jumped 34 percent in the third quarter due to lower amortization costs and increased sales of its multiple sclerosis drug Tysabri.
Drugmaker Pfizer's 3Q profit jumps 26 percent on cost cuts; more expected with Wyeth deal doneOctober 20th, 2009 Pfizer 3Q profit jumps 26 percent on cost cuttingTRENTON, N.J. — Drugmaker Pfizer Inc.
Medco says it will run clinical trial to compare blood thinners Plavix and EffientOctober 19th, 2009 Medco plans to compare Plavix, Effient in studyNEW YORK — Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with the newer Effient.
Baxter adjusted profit tops estimates, but currency exchange hits sales; company lifts outlookOctober 15th, 2009 Baxter International 3Q profit rises 12 percentNEW YORK — Specialty drug and medical device maker Baxter International Inc. said Thursday its profit grew 12 percent in the third quarter despite unfavorable currency exchange rates that held back its sales.
UBS analyst boosts price target for Amgen stock, citing osteoporosis drug, stable businessOctober 12th, 2009 UBS analyst boosts Amgen price targetNEW YORK — A UBS analyst on Monday boosted his price target on Amgen Inc., saying the launch of the company's osteoporosis drug denosumab should drive the stock's value. UBS analyst Maged Shenouda boosted his outlook to "Buy" from "Neutral" and now expects shares to reach $70 apiece over the next 12 months, up from prior expectations of $63 apiece.
SciClone Pharma shares dive after company halts trial of RP101 for pancreatic cancerOctober 5th, 2009 SciClone tumbles after cancer drug trial stopsNEW YORK — Shares of SciClone Pharmaceuticals Inc. dropped Monday after the company suspended a study of its drug candidate RP101, which was intended as a treatment for late stage pancreatic cancer.
Walgreen 4th-quarter profit dips, but prescription drugs push sales higher, topping forecastSeptember 30th, 2009 Walgreen 4Q profit falls, but results top forecastNEW YORK — Drugstore operator Walgreen Co. said prescription drug sales rose in the fiscal fourth quarter, pushing the company's results past Wall Street expectations and lifting shares to an annual high.
